These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26577521)

  • 1. Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers.
    Rhodius-Meester HF; Koikkalainen J; Mattila J; Teunissen CE; Barkhof F; Lemstra AW; Scheltens P; Lötjönen J; van der Flier WM
    J Alzheimers Dis; 2016; 50(1):261-70. PubMed ID: 26577521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
    Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients.
    Choo IH; Ni R; Schöll M; Wall A; Almkvist O; Nordberg A
    J Alzheimers Dis; 2013; 33(4):929-39. PubMed ID: 23047371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.
    Koppara A; Wolfsgruber S; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Jessen F; Kornhuber J; Wagner M
    J Alzheimers Dis; 2016; 49(2):547-60. PubMed ID: 26484902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal prediction of dementia with up to 10 years follow up: the Gothenburg MCI study.
    Eckerström C; Olsson E; Klasson N; Berge J; Nordlund A; Bjerke M; Wallin A
    J Alzheimers Dis; 2015; 44(1):205-14. PubMed ID: 25201779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mild cognitive impairment: clinical and imaging profile in a memory clinic setting in India.
    Alladi S; Shailaja M; Mridula KR; Haritha CA; Kavitha N; Khan SA; Divyaraj G; Kaul S
    Dement Geriatr Cogn Disord; 2014; 37(1-2):113-24. PubMed ID: 24135787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment.
    Kandel BM; Avants BB; Gee JC; Arnold SE; Wolk DA;
    J Alzheimers Dis; 2015; 46(4):901-12. PubMed ID: 25881908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.
    Tiepolt S; Patt M; Hoffmann KT; Schroeter ML; Sabri O; Barthel H
    J Alzheimers Dis; 2015; 47(3):539-43. PubMed ID: 26401690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
    Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
    Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease state fingerprint in frontotemporal degeneration with reference to Alzheimer's disease and mild cognitive impairment.
    Muñoz-Ruiz MÁ; Hartikainen P; Hall A; Mattila J; Koikkalainen J; Herukka SK; Julkunen V; Vanninen R; Liu Y; Lötjönen J; Soininen H
    J Alzheimers Dis; 2013; 35(4):727-39. PubMed ID: 23455991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment.
    Schmand B; Eikelenboom P; van Gool WA;
    J Alzheimers Dis; 2012; 29(3):641-8. PubMed ID: 22297644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
    J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
    Spellman DS; Wildsmith KR; Honigberg LA; Tuefferd M; Baker D; Raghavan N; Nairn AC; Croteau P; Schirm M; Allard R; Lamontagne J; Chelsky D; Hoffmann S; Potter WZ; ;
    Proteomics Clin Appl; 2015 Aug; 9(7-8):715-31. PubMed ID: 25676562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
    Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.